Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FA1H9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $85,000
Award facts
- Contract value 100% obligated
- $85,000.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $85,000.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on January 5, 2026, with completion scheduled for January 6, 2026. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a direct delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis, making it a specialized therapeutic product within the federal medical supply chain.
This delivery order is issued under AmerisourceBergen's prime IDC vehicle SPE2DX, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support contract for the Defense Health Agency and broader military healthcare systems. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies supporting military and veteran healthcare needs. The firm fixed pricing structure and rapid completion timeline reflect the operational flexibility inherent in the broader IDC framework, enabling the Defense Logistics Agency to efficiently procure specialized pharmaceutical products to support ongoing military medical operations worldwide.
Quick answers
Who was awarded contract SPE2DR26FA1H9?
SPE2DR26FA1H9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FA1H9 worth?
The government has obligated $85,000 on SPE2DR26FA1H9.
Is contract SPE2DR26FA1H9 an order under another contract?
Yes. SPE2DR26FA1H9 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA1H9 competed?
The extent of competition for SPE2DR26FA1H9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award